Cardiol Therapeutics to Present at B. Riley Securities Summit
Cardiol Therapeutics will outline its clinical progress in heart disease therapy during a fireside chat at the B. Riley Securities Mind, Muscle & Vision Summit. The session is scheduled for July 16, 2026, at 12:20 p.m. EDT, held at the InterContinental Boston Hotel in the Abigail Adams Salon B.
The Toronto-based life sciences firm is currently focused on its lead small-molecule candidate, CardiolRx. This drug aims to modulate the inflammasome pathway, a key driver in inflammation and fibrosis linked to conditions like pericarditis, myocarditis, and heart failure. The company is currently advancing the pivotal Phase III MAVERIC trial for recurrent pericarditis, following a successful pilot study and an Orphan Drug Designation from the U.S. FDA.
Beyond the MAVERIC program, the company is evaluating the ARCHER study data regarding acute myocarditis, a condition that remains a primary cause of sudden cardiac death in individuals under age 35. Development efforts also extend to CRD-38, a novel subcutaneous formulation targeting inflammatory heart disease, a sector with annual U.S. healthcare costs exceeding $30 billion.
Comments (0)
No comments yet. Be the first!